A B S T R A C T
Atrial fibrillation (AF) is the most frequent arrhythmia in common clinical practice and its prevalence is markedly increased among patients with chronic kidney disease (CKD). The presence of CKD increases the incidence of AF and vice versa. Both AF and CKD increase the risk of stroke or systemic thromboembolism and oral anticoagulation is the mainstay for thromboembolic event prevention in patients with AF. Novel oral anticoagulants (NOACs) are nowadays often used in patients with AF and CKD, but they display a variable degree of renal elimination and the risk of accumulation and bleeding increases among patients with CKD in particular as kidney disease progresses. While recent data have demonstrated that patients with Stage 3 CKD benefit even more from oral anticoagulation therapies in comparison with patients with normal renal function, relatively little is known about the best choice of anticoagulation in patients with advanced and, in particular, end-stage renal disease, as these patients were excluded from all pivotal Phase 3 NOACs trials. This review summarizes current knowledge on the efficacy and safety of these agents in individuals with CKD and provides CKD stage-specific recommendations.
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I N T R O D U C T I O N
Patients with chronic kidney disease (CKD) frequently receive anticoagulation or antiplatelet therapy due to atrial fibrillation (AF), coronary artery disease, thromboembolic disease or peripheral artery disease. Of these conditions, AF is particularly common, is the most frequent arrhythmia in clinical practice and carries an important morbidity and mortality burden. The prevalence of AF markedly increases with CKD stage and is 10-to 20-fold elevated in patients on haemodialysis compared with non-renal patients [1] . Conversely, the presence of AF may contribute to the progression of CKD. Thus, in a large population-based study with 10 328 participants, reduced kidney function was strongly associated with AF independent of other risk factors [2] .
Despite recognizing that CKD independently increases the risk of thromboembolism related to AF [3] , management of AF in this population is complex given the fact that CKD itself is an established risk factor for bleeding events [1, 4] . Nevertheless, oral anticoagulation is the mainstay for thromboembolic event prevention in CKD patients with AF, and hence novel oral anticoagulants [NOACs; sometimes also referred to as 'non-vitamin K antagonist oral anticoagulants' or 'direct oral anticoagulants' (DOACs)] could be a promising therapeutic option. However, as all of these compounds exhibit renal elimination, they carry a risk of accumulation and bleeding.
For this narrative review, PubMed was searched for publications using the term 'NOAC' and 'DOAC' or 'dabigatran', 'rivaroxaban', 'apixaban', 'edoxaban' and 'chronic kidney disease'. Of the articles that were found, those on biochemistry, chemistry and veterinary medicine were deleted. Similarly, articles published in languages other than English were deleted. After deleting duplicates, 117 publications were left. Emphasis was then placed on original work, work in humans and, in particular, on randomized controlled trials (RCTs). Cost analyses were ignored, given the rapidly changing cost environments, country-specific aspects and potential bias.
N O A C s
For decades vitamin K antagonists (VKAs), primarily warfarin or phenprocoumon, were the only option for the prevention of thromboembolic events in patients with AF. However, in CKD patients, VKAs are difficult to use because of relatively unpredictable pharmacokinetics and pharmacodynamics. Thus, compared with patients with a glomerular filtration rate (GFR) >30 mL/min, those with a GFR <30 mL/min required significantly lower warfarin dosages, spent less time with their international normalized ratio (INR) within the target range, and were more frequently overanticoagulated [5] . The latter not only contributes to an increased number of bleeding episodes but may also accelerate progression of CKD via haemorrhage within tubules (see below). A key reason underlying the problems of VKA dosing is the frequent vitamin K deficiency in advanced CKD due to dietary restrictions, altered eating habits and potentially impaired vitamin K recycling in CKD [5, 6] .
Compared with VKAs, NOACs have a more predictable effect by directly inhibiting the activation of coagulation factors that act late in the coagulation cascade ( Figure 1) . Compared with VKAs, they display a more rapid onset of action, shorter half-life, lack the need for regular laboratory monitoring and lack diet and drug interactions.
Dabigatran was the first US Food and Drug Administration (FDA)-approved NOAC ( Table 1 ). The FDA-recommended dose of dabigatran in patients with a GFR > 30 mL/min is 150 mg twice daily. However, the European Society of Cardiology (ESC) guidelines recommend patients with a GFR of 30-49 mL/min use a reduced 110 mg dose. Based on pharmacokinetic modelling, the FDA, but not the European Medicines Agency (EMA), also approved a lower dose of dabigatran 75 mg twice daily in patients with a GFR of 15-30 mL/min [7, 8] ( Figure 2 ). Rivaroxaban, apixaban and edoxaban are direct factor Xa inhibitors (Table 1) . Rivaroxaban (20 mg once a day), edoxaban (60 mg once a day) and apixaban (5 mg twice a day) do not require any dose adjustment in patients with a GFR > 50 mL/min. The FDA has approved rivaroxaban at 15 mg daily and edoxaban at 30 mg daily in patients with a GFR of 15-49 mL/min (Figure 2) . A reduced dose of apixaban is recommended if two of the following three criteria are present: serum creatinine 1.5 mg/dL, age 80 years, body weight 60 kg (Figure 2 ).
CKD STAGE AND ORAL ANTICOAGULATION
Even though the prevalence of AF in CKD patients is markedly increased in comparison with the general population, there are sparse prospective data concerning the efficacy and safety of oral anticoagulation in this population. Our current knowledge is mainly based on registries and post hoc analyses of RCTs that demonstrate a benefit from oral anticoagulation, with a reduction of thromboembolic risk ranging from 16 to 60% [9, 10] . Only recently a prospective study demonstrated clear evidence for benefit from oral anticoagulation in patients with CKD Stage 3; in fact even greater compared with individuals with normal renal function [11] . However, the picture still remains blurred for patients with more advanced disease, in particular dialysis-dependent CKD.
Moderate CKD Stage 3 (GFR 30-59 mL/min)
The ESC recommends the use of anticoagulation in patients with moderate CKD according to the risk as determined by the ESC algorithm [12] . The recommendation regarding a reduced dose of NOACs in CKD is based on secondary analyses of the Phase 3 NOACs trials. The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial assessed two fixed doses of dabigatran versus warfarin. Compared with warfarin, dabigatran 150 mg significantly reduced the event rates of stroke and systemic embolism, whereas non-inferiority was shown for the dose of 110 mg [13] . Major bleeding episodes were significantly reduced only at the 110 mg dose. A subgroup analysis of the RE-LY trial, which focused on patients with a GFR of 30-49 mL/min, demonstrated a lower risk of stroke/systemic embolism and a similar risk of major bleeding with dabigatran compared with warfarin [14] (Figure 3) . In a secondary analysis of the ROCKET-AF trial among patients with mild or moderate renal impairment, rivaroxaban preserved the benefit of warfarin in preventing stroke and systemic embolism, while bleeding events were similar and fatal bleeding occurred less often with rivaroxaban [15] . With respect to apixaban, in a secondary analysis of the ARISTOTLE study, where the risk of systemic thromboembolism and bleeding was evaluated in relation to renal function, apixaban was more effective than warfarin in preventing stroke and systemic thromboembolism and reducing the incidence of major bleeding. Patients with a GFR 50 mL/min demonstrated the greatest benefit [19] (Figure 3 ). Finally, Bohula et al. [17] assessed the efficacy and safety of edoxaban (60 mg daily or 30 mg daily if GFR < 30-50 mL/min) versus warfarin in the [14] , the ROCKET-AF trial [15] , the ARISTOTLE trial [16] and the ENGAGE AF-TIMI 48 trial [17] . (B) Annual event rate of major bleeding events at different degrees of renal impairment and in the whole study population based on the RE-LY trial, the ROCKET-AF trial, the ARISTOTLE trial and the ENGAGE AF-TIMI 48 trial. Adapted from Reinecke et al. [18] .
Novel oral anticoagulants ENGAGE AF-TIMI 48 trial [20] . In patients with impaired renal function, a reduced dose of edoxaban was comparable to warfarin for preventing stroke or systemic embolism and resulted in significantly fewer major bleeding episodes [17] . Meta-analyses of NOACs in moderate CKD conclude that there is either no difference or a favourable risk-benefit profile of all four NOACs when compared with warfarin. In analysing a number of RCTs in CKD patients, Harel et al. [21] found no significant difference in efficacy and safety between NOACs and VKAs among patients with CKD. The authors attributed this effect to the relatively intense monitoring of warfarintreated patients, which resulted in 62% time-in-therapeutic range compared with 55% noted in common clinical practice. Another meta-analysis reached the same conclusion, namely, similar efficacy and safety of NOACs compared with warfarin across different levels of renal function [22] . In contrast, three other systematic reviews and meta-analyses arrived at opposite conclusions: first, Del-Caprio et al. [23] reported in patients with mild or moderate CKD a reduced risk of stroke or systemic thromboembolism with NOACs compared with warfarin, and this was more pronounced at lower levels of renal function. NOACs also demonstrated a trend towards fewer bleeding complications compared with warfarin irrespective of kidney function [23] . In a second meta-analysis [24] , NOACs were at least as effective as VKAs, with reduced risks of major bleeding and thrombosis. A greater treatment effect for thrombosis was noted in patients with a GFR < 50 mL/min. Importantly, this analysis noted a linear relationship between the relative risk of major bleeding and the extent to which the particular NOAC was excreted by the kidneys: reductions in bleeding risk were 48% for apixaban, 26% for rivaroxaban and 27% for edoxaban, whereas for dabigatran an increase of 1% occurred [24] . Third, in a further recent meta-analysis study, NOACs were associated with a 21% and 26% relative reduction of thromboembolic endpoints and major bleeding episodes, respectively, in comparison with warfarin. Furthermore, comparisons of different NOACs suggested that apixaban and edoxaban exhibited the best net clinical profile in regard to efficacy and safety [25] .
In conclusion, even though some clinical data demonstrate the superior efficacy and safety of NOACs compared with warfarin in patients with CKD Stage 3, the superiority is often marginal and a high number of patients needed to treat (often >200) is required to achieve a clear benefit of NOACs versus warfarin. Among the NOACs, even though direct head-to-head comparisons between them are missing, two meta-analyses studies describe a better safety and efficacy profile for apixaban and edoxaban compared with rivaroxaban and dabigatran.
Severe CKD Stage 4 (GFR 15-29 mL/min)
The ESC guideline suggests the use of antithrombotic therapy in patients with severe CKD according to their risk [12, 26] . Clinical data concerning the effectiveness and safety of NOACs in patients with advanced CKD are insufficient. In all the studies mentioned above, patients with a GFR < 30 mL/min (dabigatran, rivaroxaban and edoxaban) or GFR < 25 mL/min (apixaban) were excluded. Thus the ESC and other societies recommend against their use and favour the use of warfarin [12, 26] . Hence, even though the FDA and EMA have approved reduced doses of NOACs in patients with a GFR of 15-29 mL/ min, these dose recommendations are largely based on pharmacokinetic stimulations and there are limited effectiveness and safety outcome data [8, [27] [28] [29] . However, one small retrospective cohort study in 146 adults with a creatinine clearance < 25 mL/min noted no significant difference in the number of stroke or major bleeding events in patients taking either apixaban or warfarin [30] .
To add to these difficulties, pivotal clinical trials on NOACs used creatinine clearance for patient recruitment, and dose adjustment and FDA recommendations were based on creatinine clearance or Cockroft-Gault estimates of GFR. Both may show considerable differences to the GFR estimated via the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, which is broadly used nowadays [31] . This was nicely shown in a subgroup analysis of the RE-LY trial, where GFR was estimated with the Cockcroft-Gault, CKD-EPI, and Modification of Diet in REnal Disease (MDRD) equations. Approximately half of the participants assumed to have a GFR >80 mL/min using the Cockcroft-Gault formula were reclassified as having a GFR <80 mL/min using the CKD-EPI equation [14] .
End-stage renal disease CKD Stage 5 (GFR <15 mL/min)
The big dilemma in patients with dialysis-dependent CKD and coexisting AF is the increased risk of thromboembolism versus a higher risk of bleeding as a result of uraemic platelet dysfunction and other factors. Oral anticoagulation and particularly VKA therapy for patients with AF and dialysis-dependent CKD is still a matter of debate, given the lack of prospective RCTs. A number of studies describe either no benefit or even a paradoxically increased risk of stroke and death in patients with AF taking VKAs when compared with patients with no anticoagulation [32, 33] . Significant benefit from oral anticoagulation was only described in a Danish study, which, unfortunately, lumped together haemodialysis, peritoneal dialysis and transplant patients into a 'renal replacement' group [9, 34] . The inclusion of transplant patients renders any conclusions from this latter study difficult. Finally, it is important to note that AF, at least in haemodialysis patients, is not only common but largely confined to the time on dialysis and the subsequent 4 h, i.e. the time period when patients are heparinized anyway [35] .
Owing to a lack of clear evidence that oral anticoagulation exhibits a reasonable benefit-risk ratio in AF patients with endstage renal disease, the ESC does not give any recommendations, whereas other societies such as the Canadian Cardiovascular Society caution against the routine use of any oral anticoagulation therapy in this situation [12, 26] . With respect to NOACs, there are no efficacy and outcome trial data for such patients, so their use in CKD Stage 5 is presently not recommended.
Despite the above restrictions and recommendations, 'reallife scenarios' suggest that NOACs are prescribed to dialysis patients. For example, in an American database encompassing > 30 000 dialysis patients, 6% were started on dabigatran or rivaroxaban between 2010 and 2014. In these patients, administration of NOACs was associated with a higher risk of hospitalization or death from bleeding when compared with warfarin [36] .
As already mentioned above, apixaban, with its particular pharmacokinetics, is probably the safest NOAC in end-stage renal disease. In fact, based on pharmacokinetic modelling, low-dose apixaban has been licensed for use in dialysis patients by the FDA but not the EMA. In a recent study, 2.5 and 5 mg apixaban were given for 8 days to patients on maintenance haemodialysis. The reduced dose of 2.5 mg twice daily in patients on haemodialysis resulted in drug exposure that was comparable to the standard dose in patients with preserved renal function, whereas the 5 mg dose led to supratherapeutic levels [37] . However, we would like to stress that first, it is presently uncertain whether any oral anticoagulation is better than none in dialysis patients with AF (see discussion above) and second, studies directly comparing VKAs with apixaban only just started in dialysis patients (see below).
Taken together, we discourage the use of VKAs in patients with AF and dialysis-dependent CKD [34] and we caution against the use of NOACs in such patients until effectiveness and safety data are available.
A N T I C O A G U L A T I O N -R E L A T E D N E P H R O P A T H Y
Anticoagulant-related nephropathy (initially termed warfarin-related nephropathy) is a novel and possibly underdiagnosed type of acute kidney injury associated with excessive oral anticoagulation therapy. Initially described by Brodsky et al. [38] , it is histologically characterized by glomerular haemorrhage that results in the formation of red blood cell casts within renal tubules and acute tubular injury. Apart from overanticoagulation and glomerular haemorrhage, other warfarin-related mechanisms have been also suggested, including renal vascular calcification, atheroembolism and interstitial nephritis. Recent case reports also describe cases of acute kidney injury associated with dabigatran use [39] and in a 5/6 nephrectomy rat model, dabigatran induced dose-dependent glomerular haemorrhage. The histological findings in CKD rats treated with dabigatran were similar to those found in rats treated with warfarin, including glomerular haemorrhage and acute tubular injury with red blood cell casts in the tubules [40] . In a post hoc analysis of the RE-LY trial assessing the effects of warfarin and dabigatran on kidney function in patients with AF, GFR declined similarly in all treatment groups, except for patients receiving warfarin with an INR out of the therapeutic range > 65% who exhibited an accelerated loss of renal function [41] . In line with these data, among Asians with AF, dabigatran was found to be associated with a lower risk of acute kidney injury than warfarin [42] . The authors associated this effect with the reduced number of thromboembolic events (e.g. renal infarction) and major bleeding events for dabigatran versus warfarin. Hence, if dose-dependent dabigatranrelated nephropathy exists, as demonstrated in rodents [40] , then over anticoagulation is probably the pathophysiological mechanism and a lower dose of dabigatran might result in less kidney damage.
M O N I T O R I N G A N D A N T A G O N I S M O F N O A C
Treatment with this class of drugs requires rather high vigilance, given the need for dose adaptations in the various CKD stages and the risk of bleeding from overanticoagulation. A particular concern is acute-on-chronic kidney injury with rapid deterioration of renal function. Patients need to be aware of such conditions and clinicians should pay particular attention with closer follow-up. In more stable patients on NOACs, renal function needs to be monitored at least annually to detect changes in renal function and to adapt the dose accordingly. If renal function is impaired, the European Heart Rhythm Association's practical guide recommends renal function to be monitored every 6 months for GFR 30-60 mL/min and every 3 months for GFR < 30 mL/min in patients with AF receiving an NOAC [12, 43] .
In contrast to VKAs, NOACs do not require routine monitoring given their predictable pharmacokinetic profile. If monitoring is desired, e.g. to assess potential drug accumulation in CKD, routine tests like INR or partial thromboplastin time (PTT) are not useful. Rather, for dabigatran, thrombin time (TT) or ecarin clotting time (ECT) needs to be measured, while for the factor Xa inhibitors, anti-Xa activity should be assessed (Table 1) .
Bleeding management in patients receiving NOACs does not differ from that with other anticoagulants and conventional measurements such as fluid resuscitation and the use of blood products should be as required [44] . Specific NOAC antagonists are in development and show promising effects. Andexanet alfa, a universal factor Xa reversal agent, was able to reverse the anticoagulant effects of rivaroxaban and apixaban in a dose-dependent manner. A Phase 3 prospective, clinical trial in patients with acute major bleeding (ANNEXA-4 NCT02329327) is currently recruiting patients. Idarucizumab, a monoclonal antibody that binds dabigatran with a very high affinity, was able to rapidly and completely reverse the anticoagulant activity of dabigatran in 88-98% of patients [45] . Finally, aripazine, a cationic small molecule designed to bind NOACs, has been shown to reverse the anticoagulant effect of 60 mg edoxaban [46] (Table 1) .
O N G O I N G S T U D I E S
The safety and efficacy of apixaban versus VKA in patients with AF and end-stage kidney disease will be assessed in two upcoming trials. [47] . Unfortunately, none of these trials in dialysis patients included a third arm, namely, no oral anticoagulation or intervention.
C O N C L U S I O N
Decisions on whether and which type of oral anticoagulant to use in patients with CKD and AF are strongly affected by the CKD stage. In CKD Stage 3, there is some, albeit not consistent, evidence that NOACs exhibit greater efficacy and/or better safety compared with warfarin. However, this comes at a substantial financial burden given the high price of NOACs compared with warfarin and the high numbers needed to treat to prevent one thromboembolic event or one bleeding episode. Importantly, patients receiving NOACs need regular checks of their renal function to avoid overdosing on NOACs, in particular in situations prone to acute-on-chronic kidney injury. In such patients, apixaban, at least theoretically, should be the safest of the licensed NOACs given its relatively low renal elimination. In more advanced CKD, i.e. Stage 4 and particularly in Stage 5, NOACs are currently not recommended given the paucity of RCT data [13, 20, 48, 49] and concerns of overdosing with the risk of bleeding and anticoagulant-related nephropathy. If risk stratification suggests that oral anticoagulation is indicated [26, 50] , VKAs should be used instead of NOACs in CKD Stage 4 and 5 patients until more clinical data are available. In our opinion, dialysis-dependent CKD with AF is an exception to this recommendation, given the conflicting data on the efficacy and major concerns about the safety of vitamin K antagonism in dialysis patients (Figure 4) .
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